CEO of CardioNet Adopts Rule 10b5-1 Plan
August 16 2012 - 5:12PM
Business Wire
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical
technology company with a current focus on the diagnosis and
monitoring of cardiac arrhythmias, announced today that CardioNet’s
President and Chief Executive Officer, Joseph Capper, has adopted a
Rule 10b5-1 trading plan to purchase shares of the Company’s common
stock over time as part of his individual investment strategy. The
trading plan is being established in accordance with Rule 10b5-1
under the Securities Exchange Act of 1934 and CardioNet’s policies
regarding stock transactions.
Rule 10b5-1 permits corporate officers and directors to adopt
written, pre-arranged stock trading plans when they are not in
possession of material, non-public information. Using these plans,
insiders can gradually adjust their investment portfolios and
spread stock trades over a period of time regardless of any
material, non-public information they may receive after adopting
their plans. The transactions under these plans will be disclosed
publicly through Form 144 and Form 4 filings with the Securities
and Exchange Commission.
Mr. Capper’s plan covers the purchase of up to 75,000 shares.
Under the terms of the plan, purchases can be made from time to
time starting August 17, 2012 through November 1, 2012 and may be
amended in accordance with the plan. The stock to be purchased will
be acquired in the open market.
About CardioNet
CardioNet is a leading provider of ambulatory, continuous,
real-time outpatient management solutions for monitoring relevant
and timely clinical information regarding an individual’s health.
CardioNet's initial efforts are focused on the diagnosis and
monitoring of cardiac arrhythmias, or heart rhythm disorders, with
a solution that it markets as Mobile Cardiac Outpatient TelemetryTM
(MCOTTM). More information can be found at
http://www.cardionet.com.
Forward-Looking Statements
This document includes certain forward-looking statements within
the meaning of the “Safe Harbor” provisions of the Private
Securities Litigation Reform Act of 1995 regarding, among other
things, our growth prospects, the prospects for our products and
our confidence in the Company’s future. These statements may be
identified by words such as “expect,” “may,” “anticipate,”
“possible,” “estimate,” “potential,” “intend,” “plan,” “believe,”
“forecast,” “promises” and other words and terms of similar
meaning. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any
of them, and could cause actual outcomes and results to differ
materially from current expectations. These factors include, among
other things, the effect of the cardioCORE acquisition on our
business operations and successful integration into our business,
financial results, effectiveness of our efforts to address
operational initiatives, including cost savings initiatives that
affect our business, changes to insurance coverage, relationships
with our government and commercial payors and reimbursement levels
for our products, the success of our sales and marketing
initiatives, our ability to attract and retain talented executive
management and sales personnel, our ability to identify acquisition
candidates, acquire them on attractive terms and integrate their
operations into our business, the commercialization of new
products, market factors, internal research and development
initiatives, partnered research and development initiatives,
competitive product development, changes in governmental
regulations and legislation, the continued consolidation of payors,
acceptance of our new products and services and patent protection,
adverse regulatory action and litigation success. For further
details and a discussion of these and other risks and
uncertainties, please see our public filings with the Securities
and Exchange Commission, including our latest periodic reports on
Form 10-K and 10-Q. We undertake no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events, or otherwise.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024